ECSP045469A - El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas - Google Patents
El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadasInfo
- Publication number
- ECSP045469A ECSP045469A EC2004005469A ECSP045469A ECSP045469A EC SP045469 A ECSP045469 A EC SP045469A EC 2004005469 A EC2004005469 A EC 2004005469A EC SP045469 A ECSP045469 A EC SP045469A EC SP045469 A ECSP045469 A EC SP045469A
- Authority
- EC
- Ecuador
- Prior art keywords
- cyanopirrolidins
- replaced
- preparations containing
- associated diseases
- combination preparations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Se describen métodos y composiciones para el tratamiento de hiperlipidemia y condiciones asociadas con la misma, tales como CHD, ataque isquémico, restenosis después de angioplastía, enfermedad vascular periférica, claudicación intermitente, infarto al miocardio (por ejemplo, necrosis y apoptosis), dislipidemia y lipemia posprandial. Los métodos incluyen la administración de una cantidad terapéuticamente efectiva de un compuesto de la fórmula (I), en donde: R es adamantilo sustituido; y N es de 0 a 3; en forma libre o en forma de sal de adición de ácido, y un vehículo farmacéuticamente aceptable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38522002P | 2002-06-03 | 2002-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP045469A true ECSP045469A (es) | 2005-01-28 |
Family
ID=29712145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2004005469A ECSP045469A (es) | 2002-06-03 | 2004-12-01 | El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas |
Country Status (26)
Country | Link |
---|---|
US (2) | US20050176806A1 (es) |
EP (1) | EP1513519B1 (es) |
JP (2) | JP2005532338A (es) |
KR (1) | KR20050012771A (es) |
CN (2) | CN100402026C (es) |
AT (1) | ATE422884T1 (es) |
AU (2) | AU2003245903B2 (es) |
BR (1) | BR0311535A (es) |
CA (1) | CA2487297C (es) |
CY (1) | CY1112800T1 (es) |
DE (1) | DE60326232D1 (es) |
DK (1) | DK1513519T3 (es) |
EC (1) | ECSP045469A (es) |
ES (1) | ES2321600T3 (es) |
HK (1) | HK1074794A1 (es) |
IL (1) | IL165181A (es) |
MX (1) | MXPA04012149A (es) |
NO (1) | NO333585B1 (es) |
NZ (1) | NZ536832A (es) |
PL (1) | PL210408B1 (es) |
PT (1) | PT1513519E (es) |
RU (1) | RU2362555C2 (es) |
SG (1) | SG154333A1 (es) |
SI (1) | SI1513519T1 (es) |
WO (1) | WO2003101448A1 (es) |
ZA (1) | ZA200409136B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1513519T3 (da) * | 2002-06-03 | 2009-06-02 | Novartis Ag | Anvendelse af substituerede cyanopyrrolidiner til behandling af hyperlipidæmi |
AR041089A1 (es) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
PT1715893E (pt) * | 2004-01-20 | 2009-10-20 | Novartis Pharma Ag | Formulação para compressão directa e processos |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
WO2006083214A1 (en) * | 2005-02-02 | 2006-08-10 | Astrazeneca Ab | Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor |
AU2006239929B2 (en) | 2005-04-22 | 2011-11-03 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-IV inhibitors |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
EP2114154B1 (en) * | 2007-02-08 | 2013-08-28 | Merck Sharp & Dohme Corp. | Method of treating atherosclerosis, dyslipidemias and related conditions |
EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
CN102918027A (zh) | 2010-04-06 | 2013-02-06 | 艾尼纳制药公司 | Gpr119受体调节剂和对与所述受体有关的障碍的治疗 |
AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
KR101298788B1 (ko) * | 2011-03-15 | 2013-08-22 | 보령제약 주식회사 | 안정성이 개선된 복합제제 |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EA021236B1 (ru) * | 2012-10-03 | 2015-05-29 | Дафот Энтерпраизес Лимитед | Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
CA2979033A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
CN110996951A (zh) | 2017-04-03 | 2020-04-10 | 科赫罗斯生物科学股份有限公司 | 治疗进行性核上性麻痹的PPARγ激动剂 |
CN113811359A (zh) * | 2019-03-22 | 2021-12-17 | 拉什大学医学中心 | 用于溶酶体贮积症的经鼻基因递送和口服肉桂酸、油酰胺或吉非贝齐的组合 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2572399B1 (fr) * | 1984-10-31 | 1987-01-16 | Panmedica Sa | Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant |
DE122010000020I1 (de) * | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
AU766219B2 (en) * | 1998-02-02 | 2003-10-09 | 1149336 Ontario Inc. | Method of regulating glucose metabolism, and reagents related thereto |
DE19828114A1 (de) * | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
DE19828113A1 (de) * | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
CN1332726A (zh) * | 1998-11-02 | 2002-01-23 | 卫福有限公司 | 吡咯烷化合物及其药物用途 |
CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
JP4232332B2 (ja) * | 1999-11-10 | 2009-03-04 | 末藏 岩田 | タンク付電動床磨機用ブラシ台 |
ES2436610T3 (es) * | 2000-01-21 | 2014-01-03 | Novartis Ag | Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos |
CA2464995A1 (en) * | 2001-10-31 | 2003-05-08 | Novartis Ag | Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene |
PE20040291A1 (es) * | 2002-03-22 | 2004-07-02 | Novartis Ag | COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA |
GB0212412D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
DK1513519T3 (da) * | 2002-06-03 | 2009-06-02 | Novartis Ag | Anvendelse af substituerede cyanopyrrolidiner til behandling af hyperlipidæmi |
US7935723B2 (en) * | 2004-06-04 | 2011-05-03 | Novartis Pharma Ag | Use of organic compounds |
RU2440143C2 (ru) * | 2005-09-20 | 2012-01-20 | Новартис Аг | Применение ингибитора dpp-iv для снижения приступов гликемии |
-
2003
- 2003-06-02 DK DK03737984T patent/DK1513519T3/da active
- 2003-06-02 SG SG200608456-0A patent/SG154333A1/en unknown
- 2003-06-02 US US10/516,633 patent/US20050176806A1/en not_active Abandoned
- 2003-06-02 MX MXPA04012149A patent/MXPA04012149A/es active IP Right Grant
- 2003-06-02 CA CA2487297A patent/CA2487297C/en not_active Expired - Fee Related
- 2003-06-02 WO PCT/EP2003/005762 patent/WO2003101448A1/en active IP Right Grant
- 2003-06-02 AU AU2003245903A patent/AU2003245903B2/en not_active Ceased
- 2003-06-02 ES ES03737984T patent/ES2321600T3/es not_active Expired - Lifetime
- 2003-06-02 RU RU2004139029/14A patent/RU2362555C2/ru not_active IP Right Cessation
- 2003-06-02 JP JP2004508806A patent/JP2005532338A/ja not_active Withdrawn
- 2003-06-02 SI SI200331571T patent/SI1513519T1/sl unknown
- 2003-06-02 PL PL374016A patent/PL210408B1/pl not_active IP Right Cessation
- 2003-06-02 BR BR0311535-6A patent/BR0311535A/pt not_active IP Right Cessation
- 2003-06-02 KR KR10-2004-7019595A patent/KR20050012771A/ko active Search and Examination
- 2003-06-02 CN CNB038128446A patent/CN100402026C/zh not_active Expired - Fee Related
- 2003-06-02 DE DE60326232T patent/DE60326232D1/de not_active Expired - Lifetime
- 2003-06-02 NZ NZ536832A patent/NZ536832A/en not_active IP Right Cessation
- 2003-06-02 PT PT03737984T patent/PT1513519E/pt unknown
- 2003-06-02 AT AT03737984T patent/ATE422884T1/de active
- 2003-06-02 EP EP03737984A patent/EP1513519B1/en not_active Expired - Lifetime
- 2003-06-02 CN CNA2008100965659A patent/CN101273987A/zh active Pending
-
2004
- 2004-11-11 IL IL165181A patent/IL165181A/en not_active IP Right Cessation
- 2004-11-11 ZA ZA2004/09136A patent/ZA200409136B/en unknown
- 2004-12-01 EC EC2004005469A patent/ECSP045469A/es unknown
- 2004-12-14 NO NO20045452A patent/NO333585B1/no not_active IP Right Cessation
-
2005
- 2005-08-18 HK HK05107206.0A patent/HK1074794A1/xx not_active IP Right Cessation
-
2006
- 2006-11-30 AU AU2006246483A patent/AU2006246483B9/en not_active Ceased
-
2009
- 2009-05-11 CY CY20091100499T patent/CY1112800T1/el unknown
-
2010
- 2010-04-05 JP JP2010087181A patent/JP2010155866A/ja active Pending
-
2011
- 2011-09-26 US US13/245,226 patent/US20120014907A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP045469A (es) | El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas | |
BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
DE60118003D1 (de) | Harnstoffderivate und ihre verwendung | |
CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
DK0939627T3 (da) | Pentaflourbenzensulfonamider og analoger | |
AR022469A1 (es) | Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevas sustancias | |
ATE388951T1 (de) | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes | |
ATE361287T1 (de) | Neue indol-2-on derivate | |
ATE381535T1 (de) | Phenethanolaminderivate | |
EE200300324A (et) | Asendatud alküülamiini derivaadid ja nende kasutamismeetodid | |
ES2080900T3 (es) | Derivados piranicos utiles como inhibidores de 5-lipoxigenasa. | |
HRP20041137B1 (hr) | Indolni, azaindolni i srodni heterocikliäśni 4-alkenil piperidinski amidi | |
NO20050573L (no) | 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler | |
LV12291A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
UY26895A1 (es) | Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2 | |
DE69904025D1 (de) | Kondensierte Pyrimidinderivate und diese enthaltende pharmazeutische Zubereitungen | |
ES2284970T3 (es) | Compuestos amina 1,2- y 1,3-diol y su utilizacion para el tratamiento de alzheimer. | |
DE60312154D1 (de) | 2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten | |
BR0206322A (pt) | Derivados de pirrolopiridinona substituìdos úteis como inibidores de fosfodiesterase | |
ES2157258T3 (es) | Inhibidores de la reincorporacion de dopamina destinados para el tratamiento del sindrome de parkinson. | |
SE9902147D0 (sv) | Nya föreningar och farmaceutiska kompositioner innehållande desamma | |
AR037426A1 (es) | Compuesto de quinolina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento para prepararlo y compuestos de quinolina de utilidad como intermediarios en dicho procedimiento |